Madrigal Pharmaceuticals, Inc. MDGL Gross To Net Adjustments Reserve

Segments

By product

See full

Rebates, Co-Pay Assistance, Returns, and Other$122.73M—

Chargebacks, Discounts for Prompt Pay and Other Allowances$20.83M+363%

Other financials

Income statement

See full

Revenue$311.3M+127%

Gross profit$43.5M—

Operating income-$92.7M-16.9%

Net income-$94.4M-28.9%

EPS (diluted)-$3.25-24.5%

Balance sheet

See full

Cash & equivalents$232.2M+23.1%

Total debt$377.3M+187%

Total equity$543.5M-23.5%

Total assets$1.2B+23.1%

Cash flow

See full

Operating cash flow-$167.4M-88.4%

CapEx$3.8M—

Free cash flow-$171.3M-92.7%

Valuation

See full

Market cap$11.66B+64.2%

Enterprise value$11.81B+67.5%

P/S10.3×-12.1×

Profitability

See full

Gross margin96.5%—

Operating margin-27.7%-12.2pp

Net margin-27.3%-12.0pp

FCF margin-59.8%-29.6pp

Returns & leverage

See full

Return on equity-49.3%-0.8pp

Debt / equity0.7×+0.5×

Current ratio3.5×-2.4×

Where this comes from

Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept mdgl:GrossToNetAdjustmentsReserve.

The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Madrigal Pharmaceuticals, Inc.'s gross to net adjustments reserve.

Connect your AI assistant and break it down by segment, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Madrigal Pharmaceuticals, Inc.'s gross to net adjustments reserve?: Madrigal Pharmaceuticals, Inc. (MDGL) reported gross to net adjustments reserve of $143.56M in Q1 2026.
How has Madrigal Pharmaceuticals, Inc.'s gross to net adjustments reserve changed year-over-year?: Madrigal Pharmaceuticals, Inc.'s gross to net adjustments reserve increased by 279.2% year-over-year, from $37.86M to $143.56M.